格隆汇1月8日丨君实生物(01877.HK)公告，近日，上海君实生物医药科技股份有限公司(以下简称“公司”)收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212(项目代号“JS212”)的临床试验申请获得受理。由于药品的研发周期长、审批环节多，容易受到一些不确定性因素的影响，本次临床试验申请能否获得批准存在不确定性，敬请广大投资者谨慎决策，注意防范投资风险。JS212是重组人源化抗表皮...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.